University Hospital Motol
Welcome,         Profile    Billing    Logout  
 11 Trials 
9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kala, Petr
NCT05491200 / 2021-005499-20: Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients

Recruiting
4
1608
Europe, RoW
Prasugrel based short DAPT, Prasugrel based standard DAPT, OCT guided revascularization, Angio guided revascularization
Research Maatschap Cardiologen Rotterdam Zuid, Abbott Medical Devices
ST Elevated Myocardial Infarction, Dual Antiplatelet Therapy
08/26
08/28
FAME2-10yFU, NCT06159231: FAME II-10-year Follow-Up

Completed
N/A
888
Europe, US, RoW
CoreAalst BV, Abbott Medical Devices
Coronary Artery Disease
05/24
05/24
Sumnik, Zdenek
XLHRegistry, NCT03193476: Registry for Patients With X-Linked Hypophosphatemia

Recruiting
N/A
1343
Europe, RoW
Kyowa Kirin Pharmaceutical Development Ltd, Iqvia Pty Ltd
X-Linked Hypophosphatemia
02/29
07/29
Horvath, Rudolf
NCT04527380 / 2018-000681-10: A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Active, not recruiting
3
100
Europe, RoW
Ixekizumab, LY2439821, Adalimumab
Eli Lilly and Company
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
02/24
04/28
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Recruiting
3
190
Europe, Japan, RoW
Baricitinib, LY3009104
Eli Lilly and Company
Juvenile Idiopathic Arthritis
07/31
07/31
Kopeckova, Katerina
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Active, not recruiting
3
440
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
Koubkova, Leona
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Recruiting
3
1000
Europe, Canada, Japan, RoW
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
09/28
09/29
HLX10-020-SCLC302, NCT05353257 / 2022-002226-27: A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Active, not recruiting
3
511
Europe, US, RoW
HLX10, Serplulimab, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI)
Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.
Limited-Stage Small Cell Lung Cancer
07/25
12/26
Šípek, Jan
No trials found
Slepčanová, Hana
No trials found

Download Options